---
layout: default
title: Ammonium Chloride
parent: Model Prediction Only (L5)
nav_order: 54
evidence_level: L5
indication_count: 2
---

# Ammonium Chloride
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ammonium Chloride: From Cough Syrup Ingredient to Acute Laryngopharyngitis

## One-Sentence Summary

Ammonium chloride is an ingredient in cough syrup products marketed in Canada, but the record lists no formal approved indication.
The TxGNN model predicts it may be effective for **acute laryngopharyngitis**,
but currently **0 clinical trials** and **0 publications** support this direction, so the prediction rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the record (marketed in cough syrup products) |
| Predicted New Indication | Acute laryngopharyngitis |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

A second prediction, **nasal cavity disease** (score 99.94%), also has no supporting trials or literature. The term is broad and non-specific, so it is less informative.

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ammonium chloride is a component of cough syrup products, and mechanistically it may be applicable to upper-airway conditions such as acute laryngopharyngitis.

Ammonium chloride is widely known as an expectorant in over-the-counter cough and cold products. It is thought to irritate the stomach lining, which reflexively increases respiratory tract secretions and helps loosen mucus. This would make a link to upper-airway inflammation biologically plausible. However, this comes from general pharmacology knowledge, not from the supplied data, and it has not been verified.

The prediction score is high, but without any clinical data it is only a hypothesis. The score may partly reflect general network proximity in the knowledge graph, so it should not be read as evidence of efficacy.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2245592 | DAMYLIN WITH CODEINE SYRUP | Not listed | Not listed |
| 690074 | COUGH SYRUP | Not listed | Not listed |
| 535230 | CALMYLIN | Not listed | Not listed |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the TxGNN score. There are no clinical trials, no literature, and no mechanism data. The product labels in the record also list no approved indication or safety information, so the prediction cannot be evaluated further at this stage.

**To proceed, the following is needed:**
- Health Canada package insert (warnings, contraindications, approved indications) for the three listed products
- Mechanism of action data (for example, from DrugBank)
- A more specific target disease. "Nasal cavity disease" is too broad to evaluate.
- Any clinical or observational evidence for ammonium chloride in acute laryngopharyngitis or related upper-airway conditions
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

